Could a common diabetes pill prevent dangerous pregnancy complications?

NCT ID NCT03570632

Ongoing Prevention Sponsor: Maisa N. Feghali, MD Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 4 trial tests whether taking metformin daily before 20 weeks of pregnancy can reduce the risk of high blood pressure disorders, like preeclampsia, in pregnant women with type 1 diabetes. About 60 women will receive either metformin plus standard care or standard care alone. The study aims to find a safe, effective prevention strategy for a serious complication that currently lacks proven preventive options.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Metformin
What this could lead to: If it works, this could offer a safe, daily pill to prevent dangerous pregnancy complications in women with type 1 diabetes.
What could go wrong: This is a small, early-phase trial with only 60 participants, so results may not apply to everyone. Metformin can cause stomach upset, and its effectiveness is not yet proven.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIABETES MELLITUS, TYPE 1 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

gestational diabetes Pregnancy in Diabetics type 1 diabetes mellitus type 1 diabetes mellitus 1 hypertension, pregnancy-induced prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DIABETES MELLITUS, TYPE 1 PREGNANCY IN DIABETES

Contacts and locations

Locations

Magee Womens Hospital of UPMC

Pittsburgh, Pennsylvania, 15213, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.